Sign In

Aerocrine: 3.32m EUR in new funds

16 May 2001 10:54
By Tornado Staff

Aerocrine, a Stockholm biotechnology company that patented NIOX, a nitric monitoring product which is the cause of breathing inflammations like asthma, announced a capital increase with the flotation of 2.5 million new shares.

Old shareholders like Investor, the Wallenberg family finance company, and HealthCap Venture, a venture capital fund specialised in biotech companies are underwriting the flotation said to be worth 3.32 million euro along with the new investors 6AP Fonden and Health & Brands.

Related stories
Mucosis wins Wellcome Trust award and backing from current investors
Massive £50 million Series B round for UK-based Cell Medica
€6.3 million Series C for Humedics’ liver function diagnostic device
Medication safety system provider Mint Solutions secures €4.4 million
Big VC rounds for Ganymed and MISSION to fight cancer


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Jun 28€15.0MBroadcast
Jun 18€53.0MInternet services
Jun 18€3.0MInternet services
Jun 18€5.7MSecurity
Jun 17€4.5MArtificial Intelligence
Jun 17€24.0MKnowledge management

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.